Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Authors
Keywords
HDAC Inhibitor, Urothelial Carcinoma, SAHA, Vorinostat, Necrotic Cell Death
Journal
Targeted Oncology
Volume 11, Issue 6, Pages 783-798
Publisher
Springer Nature
Online
2016-06-02
DOI
10.1007/s11523-016-0444-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells
- (2016) Meili Fu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms
- (2016) M. Pinkerneil et al. MOLECULAR CANCER THERAPEUTICS
- Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells
- (2016) Huang Zhijun et al. TUMOR BIOLOGY
- The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
- (2015) Julie Earl et al. BMC GENOMICS
- Acetylation site specificities of lysine deacetylase inhibitors in human cells
- (2015) Christian Schölz et al. NATURE BIOTECHNOLOGY
- Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response
- (2015) John A Halsall et al. Epigenetics & Chromatin
- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells
- (2014) Lorena Rosik et al. CANCER BIOLOGY & THERAPY
- Targeted therapies in urothelial carcinoma
- (2014) Monalisa Ghosh et al. CURRENT OPINION IN ONCOLOGY
- Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)
- (2014) Sergio Valente et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
- (2014) Judith Knievel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
- (2014) Maria Lehmann et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
- (2014) Prithviraj Bose et al. PHARMACOLOGY & THERAPEUTICS
- Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
- (2014) Datsen George Wei et al. PLoS Pathogens
- Abnormal mitosis triggers p53-dependent cell cycle arrest in human tetraploid cells
- (2013) Christian Kuffer et al. CHROMOSOMA
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
- (2013) F Lai et al. Cell Death & Disease
- Chemotherapie des Urothelkarzinoms der Harnblase – Update 2012
- (2012) G. Niegisch et al. AKTUELLE UROLOGIE
- Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity
- (2012) D. L. Fei et al. CANCER RESEARCH
- Wnt signaling pathways in urological cancers: past decades and still growing
- (2012) Shahana Majid et al. Molecular Cancer
- Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers
- (2012) Günter Niegisch et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro
- (2011) Stefan Vallo et al. ANTI-CANCER DRUGS
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors
- (2011) M. M. Singh et al. NEURO-ONCOLOGY
- 178 Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor
- (2010) S.W. Henning et al. EJC SUPPLEMENTS
- Acetylation of RNA Processing Proteins and Cell Cycle Proteins in Mitosis
- (2010) Carol Chuang et al. JOURNAL OF PROTEOME RESEARCH
- Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
- (2010) J.- H. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
- (2009) Ailsa J. Frew et al. CANCER LETTERS
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromosomal instability in bladder cancer
- (2008) Andrea R. Florl et al. ARCHIVES OF TOXICOLOGY
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
- (2008) Xiang-Jiao Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now